Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adynamic bone revisited: is there progress?

Cheryl P Sanchez1

  • 1Pediatrics, University of Wisconsin Medical School, Madison, USA. cpsanchez@wisc.edu

Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|March 17, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cortical and trabecular bone are equally affected in rats with renal failure and secondary hyperparathyroidism.

BMC nephrology·2018
Same author

Genetic Knockout and Rescue Studies in Mice Unravel Abnormal Phosphorus Threshold in Hypophosphatemic Rickets.

Endocrinology·2017
Same author

Inpatient citrate-based hemodialysis in pediatric patients.

Pediatric nephrology (Berlin, Germany)·2016
Same author

Growth-plate cartilage in chronic renal failure.

Pediatric nephrology (Berlin, Germany)·2009
Same author

Bone growth during rapamycin therapy in young rats.

BMC pediatrics·2009
Same author

Mineral metabolism and bone abnormalities in children with chronic renal failure.

Reviews in endocrine & metabolic disorders·2008
Same journal

Translational insights into extracellular vesicles in peritoneal dialysis.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

Quercetin attenuates peritoneal fibrosis by upregulating ferroptosis-related glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11) in MeT-5A and rat models: Supported by clinical mRNA expression data.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

An in vitro comparison of bacterial touch contamination prevention between a novel APD cycler connector and existing APD connectors.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

What is the effect of the assistance on the risk of transfer to HD after an unplanned peritoneal dialysis initiation? A cohort study with data from the RDPLF.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

2026 ISPD Position Statement on tracking and reporting loss from PD therapy.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same journal

Important factors in the choice of dialysis modality among Japanese patients initiating peritoneal dialysis.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
See all related articles

Adynamic bone disease is a concern for children with chronic kidney disease. Managing secondary hyperparathyroidism involves maintaining specific parathyroid hormone (PTH) levels and avoiding hypercalcemia to prevent bone complications.

Area of Science:

  • Pediatric Nephrology
  • Bone Metabolism
  • Mineral and Bone Disorders

Background:

  • Adynamic bone disease is a significant complication in pediatric patients with chronic renal failure.
  • Secondary hyperparathyroidism is common in children with chronic kidney disease and contributes to bone abnormalities.

Purpose of the Study:

  • To outline strategies for preventing adynamic bone disease in children with chronic renal failure.
  • To provide clinical recommendations for managing secondary hyperparathyroidism in this population.

Main Methods:

  • Review of clinical guidelines and recommendations for managing mineral and bone disorders in pediatric chronic kidney disease.
  • Emphasis on therapeutic targets for intact parathyroid hormone (iPTH), calcium, and phosphorus levels.

Related Experiment Videos

Main Results:

  • Maintaining iPTH levels at 2–4 times normal is recommended.
  • Avoiding hypercalcemia and keeping serum phosphorus within age-appropriate limits are crucial.
  • Utilizing less-calcemic vitamin D analogs and calcium-free, aluminum-free phosphate binders is advised.

Conclusions:

  • Careful medication management, including adjusting vitamin D, calcium salts, and other PTH-lowering agents, is essential.
  • Reducing or discontinuing medications is necessary when iPTH levels drop rapidly (< 150 pg/mL) and serum calcium is elevated (> 10 mg/dL).
  • Proactive management of secondary hyperparathyroidism is key to preventing adynamic bone disease in pediatric chronic kidney disease patients.